These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 25012983)

  • 21. A Somatostatin Receptor Subtype-3 (SST
    Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
    Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
    Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
    Reubi JC; Schonbrunn A
    Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
    Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
    Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.
    Waser B; Cescato R; Liu Q; Kao YJ; Körner M; Christ E; Schonbrunn A; Reubi JC
    Am J Pathol; 2012 May; 180(5):1942-9. PubMed ID: 22538189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
    Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
    Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
    van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
    Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
    Heidari P; Wehrenberg-Klee E; Habibollahi P; Yokell D; Kulke M; Mahmood U
    Cancer Res; 2013 Dec; 73(23):6865-73. PubMed ID: 24080280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
    Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
    Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
    Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
    Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
    Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine tumours - Medical therapy: Biological.
    Rinke A; Krug S
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.